Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$64.13M

FY 2025 · Annual

Investing Cash Flow

$65.96M

FY 2025 · Annual

Financing Cash Flow

-$1.21M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Depreciation & Amortization445K1.12M1.58M2.33M
Deferred Income Tax0000
Stock-Based Compensation698K1.48M2.26M5.13M
Change in Working Capital(1.14M)(15K)58.98M(3.23M)
Accounts Receivables0(257K)(861K)1.03M
Inventory0000
Accounts Payables(1K)659K360K(44K)
Other Working Capital(1.14M)(417K)59.48M(4.22M)
Other Non-Cash Items(200K)(3.95M)(4.07M)(4.62M)
Operating Cash Flow(18.13M)(30M)14.76M(64.13M)
Capital Expenditures(2.31M)(3.76M)(2.86M)(9.58M)
Acquisitions (Net)0000
Purchases of Investments0(145.81M)(288.4M)(193.87M)
Sales of Investments080.69M100.86M269.42M
Other Investing Activities057K00
Investing Cash Flow(2.31M)(68.83M)(190.4M)65.96M
Debt Repayment0000
Common Stock Issued000336K
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(151K)0(1.72M)(1.55M)
Financing Cash Flow119.98M0183.28M(1.21M)
Effect of Forex Changes0000
Net Change in Cash99.55M(98.83M)7.65M625K
Free Cash Flow(20.43M)(33.77M)11.9M(73.71M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$63.7M
+ D&A$2.3M
+ Stock-Based Comp$5.1M
+ Deferred Tax$0
- Working Capital-$3.2M
- Other Non-Cash-$4.6M
= Operating Cash Flow-$64.1M
- Capex-$9.6M
= Free Cash Flow-$73.7M

Analysis

FY2025 free cash flow is -$73.7M. FCF conversion is 115.7% of net income. Operating cash flow was -$64.1M, with capex of -$9.6M. The largest bridge item is Capex at -$9.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
10-QQuarterly reportAug 13, 2026
8-KCurrent reportAug 13, 2026

Does AKTS generate free cash flow?

Aktis Oncology, Inc. (AKTS) generated -$73.71M of free cash flow in fiscal 2025.

How much operating cash flow does AKTS produce?

Operating cash flow was -$64.13M, before capital expenditures of $9.58M.